(±)-AMG 487 - CAS 473719-41-4
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
(±)-AMG 487
Catalog Number:
473719-41-4
Synonyms:
Benzeneacetamide, N-((1R)-1-(3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(3-pyridinylmethyl)-4-(trifluoromethoxy)-; N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluorome
CAS Number:
473719-41-4
Description:
CXCR3 antagonist; Inhibits cell migration and metastasis
Molecular Weight:
603.59
Molecular Formula:
C32H28F3N5O4
Quantity:
Milligrams-Grams
Quality Standard:
In-house
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CCOc1ccc(cc1)n2c(=O)c3cccnc3nc2[C@@H](C)N(Cc4cccnc4)C(=O)Cc5ccc(cc5)OC(F)(F)F
InChI:
1S/C32H28F3N5O4/c1-3-43-25-14-10-24(11-15-25)40-30(38-29-27(31(40)42)7-5-17-37-29)21(2)39(20-23-6-4-16-36-19-23)28(41)18-22-8-12-26(13-9-22)44-32(33,34)35/h4-17,19,21H,3,18,20H2,1-2H3/t21-/m1/s1
InChIKey:
WQTKNBPCJKRYPA-OAQYLSRUSA-N
Targets:
CXCR
Chemical Structure
CAS 473719-41-4 (±)-AMG 487

Related CXCR Products


(±)-NBI 74330
(CAS: 473722-68-8)

Potent and selective CXCR3 antagonist

CAS 185991-07-5 AMD 3465 hexahydrobromide

AMD 3465 hexahydrobromide
(CAS: 185991-07-5)

Potent and selective CXCR4 antagonist

CAS 1204707-71-0 SRT3109

SRT3109
(CAS: 1204707-71-0)

A CXCR2 ligand

Danirixin
(CAS: 954126-98-8)

A small molecule, non-peptide CXCR2 antagonist; High affinity (IC50 for CXCL8 binding = 12.5 nM), selective, and reversible

KRH1636
(CAS: 568526-77-2)

KRH1636 is an orally active, selective and extremely potent CXC chemokine receptor 4(CXCR4) antagonist. It exhibits a potent and selective anti-HIV-1 activity. ...

Navarixin
(CAS: 862464-58-2)

Navarixin is a potent CXC chemokine receptor 2 (CXCR2) antagonist. It can be used for the treatment of Asthma and Chronic obstructive pulmonary disease. In Dec ...

TC 14012
(CAS: 368874-34-4)

CXCR4 antagonist; ACKR3 (CXCR7) agonist

CAS 473727-83-2 SCH 527123

SCH 527123
(CAS: 473727-83-2)

A potent antagonist of both CXCR1 and CXCR2 with IC50 of 42 nM and 3 nM, respectively.

LY-2510924
(CAS: 1088715-84-7)

LY-2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4). It has potential antineoplastic activity. It binds to the chemokine receptor CXCR4, thereby prev...

FC 131
(CAS: 606968-52-9)

CXCR4 antagonist

VUF 11222
(CAS: 1414376-84-3)

High affinity non-peptide CXCR3 agonist (pKi = 7.2)

CAS 155148-31-5 AMD 3100 octahydrochloride

AMD 3100 octahydrochloride
(CAS: 155148-31-5)

Highly selective CXCR4 chemokine receptor antagonist (IC50 values are 0.02 - 0.13 and > 25 μM for CXCR4 and all other chemokine receptors respectively)

CAS 211096-49-0 SB 265610

SB 265610
(CAS: 211096-49-0)

Potent CXCR2 antagonist

CAS 558447-26-0 AMD-070

AMD-070
(CAS: 558447-26-0)

Potent and selective antagonist of CXCR4 (with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay)

CAS 897657-95-3 MSX-122

MSX-122
(CAS: 897657-95-3)

A novel small molecule and partial CXCR4 antagonist

CAS 855527-92-3 NBI-74330

NBI-74330
(CAS: 855527-92-3)

A small molecule antagonist for CXCR3

AMD 3465
(CAS: 185991-24-6)

AMD 3465,a N-pyridinylmethylene monocyclam, is a selective antagonist of CXCL12/CXCR4-mediated interactions including ligand binding and receptor activation. Wi...

IT1t dihydrochloride
(CAS: 1092776-63-0)

Potent CXCR4 antagonist(IC50 = 1.1 nM in calcium mobilization assays); Orally available

IT1t
(CAS: 864677-55-4)

IT1t is a selective CXCR4 antagonist with IC50 value of 1.1 nM in calcium mobilization assays.It may be potential useful as anti-HIV agent.

CAS 266359-83-5 Reparixin

Reparixin
(CAS: 266359-83-5)

An inhibitor of CXCL8 receptor, also inhibit CXCR1 and CXCR2 activation

Reference Reading


1.An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing.
Tonn GR1, Wong SG, Wong SC, Johnson MG, Ma J, Cho R, Floren LC, Kersey K, Berry K, Marcus AP, Wang X, Van Lengerich B, Medina JC, Pearson PG, Wong BK. Drug Metab Dispos. 2009 Mar;37(3):502-13. doi: 10.1124/dmd.108.021931. Epub 2008 Dec 16.
(R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]-pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxyphenyl)-acetamide (AMG 487) is a potent and selective orally bioavailable chemokine (C-X-C motif) receptor 3 (CXCR3) antagonist that displays dose- and time-dependent pharmacokinetics in human subjects after multiple oral dosing. Although AMG 487 exhibited linear pharmacokinetics on both days 1 and 7 at the 25-mg dose, dose- and time-dependent kinetics were evident at the two higher doses. Nonlinear kinetics were more pronounced after multiple dosing. Area under the plasma concentration-time curve from 0 to 24 h [AUC((0-24 h))] increased 96-fold with a 10-fold increase in dose on day 7 compared with a 28-fold increase in AUC((0-24 h)) on day 1. These changes were correlated with time- and dose-dependent decreases in the metabolite to parent plasma concentrations, suggesting that these changes result from a decrease in the oral clearance (CL) of AMG 487 (e.
2.Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme.
Henne KR1, Tran TB, VandenBrink BM, Rock DA, Aidasani DK, Subramanian R, Mason AK, Stresser DM, Teffera Y, Wong SG, Johnson MG, Chen X, Tonn GR, Wong BK. Drug Metab Dispos. 2012 Jul;40(7):1429-40. doi: 10.1124/dmd.112.045708. Epub 2012 Apr 19.
CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharmacokinetics in humans. Although in vitro activity loss assays failed to demonstrate CYP3A4 time-dependent inhibition (TDI) with AMG 487, its M2 phenol metabolite readily produced TDI when remaining activity was assessed using either midazolam or testosterone (K(I) = 0.73-0.74 μM, k(inact) = 0.088-0.099 min(-1)). TDI investigations using an IC(50) shift method successfully produced inhibition attributable to AMG 487, but only when preincubations were extended from 30 to 90 min. The shift magnitude was ∼3× for midazolam activity, but no shift was observed for testosterone activity. Subsequent partition ratio determinations conducted for M2 using recombinant CYP3A4 showed that inactivation was a relatively inefficient process (r = 36).